ICER dings Novo's new oral diabetes drug

Novo Nordisk's oral semaglutide delivers fewer benefits to diabetics than Eli Lilly and Boehringer Ingelheim's pill Jardiance and, if priced similarly to its injectable form Ozempic, will be more expensive, the Institute for Clinical and Economic Review concluded in a draft report.